Lymphoproliferative disorders in Oxford renal transplant recipients

Bates, William; Gray, Derek W. R.; Dada, M A; Chetty, Runjan; Gatter, Ken; Davies, D.C.; Morris, Peter J.

doi:10.1136/jcp.56.6.439

Cited by 45 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most previous authors evaluating PTLD incidence in kidney recipients also reported that GI tract localization of PTLD is the most frequent involvement location [8,17]; however, controversial reports also exist with lymph nodes and the allograft as the most common involvement sites [2,18].…”

Section: Discussionmentioning

confidence: 95%

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Late-onset PTLD can be seen as late as 20 years after transplantation, is usually monoclonal and heralds a worse prognosis [46]. PTLD, irrespective of histology, is a significant cause of morbidity and mortality in transplant patients and can be fatal if untreated.…”

Section: Clinical Findingsmentioning

confidence: 99%

The radiological spectrum of pulmonary lymphoproliferative disease

Hare¹,

Souza²,

Bain³

et al. 2012

BJR

178

234

View full text Add to dashboard Cite

“…The most relevant concern is about a possible implication of CSA, as its prolonged use is considered a risk factor for lymphoproliferative disorders. Most frequently, long-term therapy with CSA is associated with B-cell lymphoma [13], whereas T-cell variants, and in particular those forms mainly involving the skin [cutaneous T-cell lymphoma (CTCL)], are reported in a minority of cases. The most recent review of the literature [14] reveals 23 cases of posttransplant primary CTCL that are, in general, erythrodermic diseases and anaplastic large-cell CTCL.…”

Section: Discussionmentioning

confidence: 99%

Recurrent lymphomatoid papulosis associated with nephrotic syndrome. An occurrence of uncertain origin

et al. 2009

View full text Add to dashboard Cite

We report on a 10-year-old child with nephrotic syndrome who developed recurrent lymphomatoid papulosis (LYP) 60 months after the first episode of proteinuria. LYP appeared when the child was taking low-dose cyclosporin and disappeared after the drug was replaced by prednisone at doses utilized for nephrotic syndrome (2 mg/kg). During the tapering of steroids, when the child was treated with low-dose prednisone (0.2 mg/kg), both LYP and nephrotic syndrome started again and required the reintroduction of prednisone to restore a normal clinical situation. This is the first case of LYP occurring in concomitance and synchronous with nephrotic syndrome. LYP was unrelated to cyclosporin (second episode after its withdrawn) but preceded the recurrence of proteinuria, suggesting a relationship with the disease activity. Even though the etiology of LYP is, in this case, uncertain, it should be considered as a clinical association of nephrotic syndrome in children and also included among potential triggers of the disease.

show abstract

Lymphoproliferative disorders in Oxford renal transplant recipients

Cited by 45 publications

References 11 publications

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

The radiological spectrum of pulmonary lymphoproliferative disease

Recurrent lymphomatoid papulosis associated with nephrotic syndrome. An occurrence of uncertain origin

Contact Info

Product

Resources

About